22 May 2013
Keywords: KV Pharmaceuticals, Ther-Rx, Baxterm Makena, Preterm birth
Article | 07 February 2011
The US Food and Drug Administration on Friday approved Makena (hydroxyprogesterone caproate) injection to reduce the risk of preterm delivery ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 February 2011
8 February 2011
21 May 2013
© 2013 thepharmaletter.com